Dade gives Abbott cardiac marker rights:
This article was originally published in Clinica
Executive Summary
Dade Behring has sublicensed to Abbott non-exclusive rights to use the emerging cardiac marker, placental growth factor (PlGF), in the development of tests for the diagnosis and prognosis of cardiovascular diseases. Studies have shown that levels of PlGF may be useful in the prognosis of acute coronary syndrome, a heart condition that impacts millions of people worldwide, said Deerfield, Illinois-based Dade.